A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 451-457

  Casal Rubio, J ^a   Firvida Perez J L ^b   Lazaro Quintela M ^a   Baron Duarte F J ^c   Alonso Jaudenes G ^d   Santome L ^e   Afonso Afonso, F J ^f   Amenedo, M ^g   Huidobro, G ^a   Campos Balea, B ^h   Lopez Vazquez M D ⁱ   Vazquez S ^h  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Complexo Hospitalario de Ourense   (Spain)

^c University Hospital of Santiago de Compostela   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL POVISA   (Spain)

^f Universidad de La Coruña   (Spain)

^g Hospital Oncologico de Galicia   (Spain)

^h SERGAS   (Spain)

ⁱ Oncology Department   (Spain)

Author keywords

Erlotinib; Maintenance chemotherapy; Non small cell lung cancer; Stage III disease

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BRONCHUS OBSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE RATE; RASH; RISK ASSESSMENT; SCORING SYSTEM; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL RATE;

EID: 84896052804     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2370-z     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Crino L, Weder W, van Meerbeeck J et al (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v103-v115
3. American Joint Committee on Cancer (2010) TNM classification of malignant tumours, lung. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) American Joint Committee on Cancer: AJCC cancer staging manual, 7th edn. Springer, New York, pp 253-270
4. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91-112
5. Auperin A, Le PC, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181-2190
6. Auperin A, Pechoux C, Pignon J et al (2006) Concomitant radio-chemotherapy base on platin compounds in patients with locally advanced non-small-cell lung cáncer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17:473-483 (Pubitemid 43329586)
7. Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:1452-1460
8. O'Rourke N, Roque IF, Farre BN et al (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev CD002140
9. Vokes EE, Herndon JE, Crawford J et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage III non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198 (Pubitemid 35191021)
10. Yamammoto N, Nakagawa K, Nishimura Y et al (2010) Phase III study comparing second and third generation regimens with concurrent Thoracic Radiotherapy in patients with unresectable stage III non-small-cell lung cáncer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739-3745
11. Huber RM, Flentje M, Schmidt M et al (2006) Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24(27):4397-4404 (Pubitemid 46630977)
12. Rivera S, Quero L, Wong Hee KS et al (2011) Targeted therapies and radiation therapy in non-small cell lung cancer. Cancer Radiother 15:527-535
13. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529
14. Perol M, Chouaid C, Perol D et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 30:3516-3524
15. Kim JC, Ali MA, Nandi A et al (2005) Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys 42:358-365 (Pubitemid 43962276)
16. Wang M, Morsbach F, Sander D et al (2011) EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 71:6261-6269
17. Sacco PC, Maione P, Rossi A et al (2011) Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol 6:171-180
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
20. Rigas JR, Carey MA, Rubin MS (2009) Efficiency of maintenance erlotinib versus placebo in patients with unresectable stage III non-small lung cancer (NSCLC) following concurrent chemoradiation (D0410, NCT00153803). J Thoracic Oncol 4:S371
21. Petrelli F, Borgonovo K, Cabiddu M et al (2011) Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anticancer Drugs 22:1010-1019
22. Novello S, Milella M, Tiseo M et al (2011) Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res 30:50
23. Carter DL, Garfield D, Hathorn J et al (2012) A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer 13:205-213
24. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010 (Pubitemid 46606390)
25. Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755-5760
26. Kelly K, Chansky K, Gaspar LE et al (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-smallcell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456
27. Huber RM, Engel-Riedel W, Kollmeier J et al (2012) GILT study: oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. ASCO Annual Meeting, Chicago (abstr No. 7001)
28. Segaert S, Van CE (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433 (Pubitemid 41222414)
29. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921 (Pubitemid 47037599)